Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017

GlobalData's clinical trial report, “Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Alexion Pharmaceuticals Inc

Omeros Corp

ChemoCentryx Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc

Laboratory Corp of America Holdings

INC Research Holdings Inc

Galenica Ltd

Amgen Inc

Alnylam Pharmaceuticals Inc

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Clinical Trials by G7 Countries: Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials 14

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials 20

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 26

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials 31

Prominent Drugs 33

Latest Clinical Trials News on Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) 35

Mar 27, 2017: Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology 35

Clinical Trial Profile Snapshots 36

Appendix 53

Abbreviations 53

Definitions 53

Research Methodology 54

Secondary Research 54

About GlobalData 55

Contact Us 55

Source 56

List of Tables

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 6

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13

Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, G7 Countries (%), 2017* 14

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18

Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, E7 Countries (%), 2017* 20

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 22

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33

List of Figures

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13

Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, G7 Countries (%), 2017* 14

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18

Proportion of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) to Gastrointestinal Clinical Trials, E7 Countries (%), 2017* 20

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33

GlobalData Methodology 54

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports